In the last two years Lupus has been prominent in highlighting new procedures deriving from stem cell (SC) transplantation in severe, relapsingarefractory, high-dose steroid-dependent SLE. After a ®rst conceptual proposal of 6 years ago, 1 three single case reports 2±4 and two editorials 5, 6 have been published in this journal. In addition, and leaving aside many case reports still in the form of conference abstracts, two other cases have been published. 6, 7 Other patients were autotransplanted because of concomitant SLE and malignant blood diseases. 8±11 Finally there are still another six cases who, together with other autoimmune patients, received only high-dose cyclophosphamide without stem cell support, 12, 13 according to a program initially developed at Johns Hopkins for severe aplastic anaemia 14 and currently de®ned as immunoablative therapy.
12
It is, of course, impossible to reach evidence-based recommendations. 15 Nevertheless some comments may be made on these new approaches, 16 which have been more widely analysed for the whole spectrum of autoimmune diseases.
17±19 As recently pointed out by van Bekkum, 17 the prevailing concept of autoimmunity dictates that cures can only be expected when the patient's autoreactive immune competent cells are replaced with cells from a healthy donor who, in addition, is not susceptible to whatever factors that break tolerance.
It is well-known that this goal has been attained in experimental autoimmunity, 20,21 including murine SLE, utilizing total body irradiation followed by allogeneic SC transplantation. In humans cures 22 but also relapses 23 have been reported in rheumatoid arthritis. It was also noticed that patients who developed graft-versus-host-disease were less relapse-prone, 24 thus suggesting the possibility of a Graft-versus-Autoimmunity effect, which has been shown experimentally. 25 Whether this effect may be utilised in future nonmyeloablative approaches 26±28 remains to be proven.
For the time being intense immunosuppression followed by autologous SC transplantation is being utilised worldwide because of its superior safety. 29 In the SLE cases there has been only one fatality in a case complicated with thrombotic thrombocytopenic purpura. 30 In all the other cases long-term remissions have been obtained, sometimes achieving total steroid-independence 3,7 and, if not, a signi®cant dosage reduction.
2,4 SLE disease scores fell in those cases where they were studied. 2, 7 However in all cases weakly positive (borderline) ANA positive tests persisted. In those cases with a combination of neoplastic blood diseases and SLE the biologic signs of the latter apparently proved to be more resistant than the actual neoplastic process, at least for 2 y of follow-up. Perhaps the most objective title of a successful case report is the one by Fouillard et al 4 in this issue, who speak of`control of disease'.
In most patients peripheral SC were utilised. The mobilisation procedure included cyclophosphamide (Cy) (4 gam 2 ), which by itself is also a powerful immunosuppressive treatment, as has been shown by the regression of gadolinium-enhancing CNS lesions in multiple sclerosis. 30 Conditioning regimens never included total body irradiation, but dose-intense protocols were generally utilised, including Cy 200 mgakg plus ATG, In most cases a 3-log T-cell depletion was performed as has been recommended, 8, 17, 29 although its real signi®cance is uncertain. Further depletion is not indicated, since its uncertain bene®t is more than counterbalanced by severe immunode®ciency. 32 In all patients, including the SLE patients, autologous transplants were followed by a long-lasting depression of B and especially T cell immunity, with extreme CD4 -penia and inversion of the CD4 aCD8 ratio. The CD4 CD45RA subset, which corresponds to naive cells recently issued by the thymus, is profoundly reduced and may take up to 2 y to recover. 33 In our lupus case 2 it took 3 y for CD4
lymphocytes to return to the normal range, although no infectious complications supervened.
Six cases of SLE have been treated with the immunoablative Johns Hopkins regimen 12 to date: two are in complete remission off immunosuppressive therapy, one has had a partial remission, and three have short follow-ups ( b 6 months), but all three are showing`dramatic improvement'.
13 Marrow SC have long been known to be resistant to Cy, possibly due to their expression of high levels of aldehyde dehydrogenase. 34 These clinical results are impressive, and of course the problem of re-infusing autoreactive lymphocytes is cancelled.
Finally will these new aggressive approaches eventually supersede other equally aggressive but not SC-dependent approaches? The overwhelming majority of SLE patients are safely controlled by conventional therapies, but there certainly is a minority who require more aggressive and ef®cient procedures. When inclusion and exclusion criteria and uniform protocols will be established in the proximate future, the time will come to program prospective randomised polycentric studies, including alternative approaches. 
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